ERBB2 and breast cancer: Trastuzumab with chemotherapy in a neoadjuvant setting resulted in significantly diminished pCR (complete pathological response) rates in HER2-positive BC patients with low PTEN expression assessed by immunohistochemistry compared to those with elevated PTEN protein levels [89].